Published in Sarcoidosis Vasc Diffuse Lung Dis on March 01, 2005
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Pleural effusions in hematologic malignancies. Chest (2004) 3.14
Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 3.02
Inflammatory markers in patients with severe burn injury. What is the best indicator of sepsis? Burns (2007) 1.70
Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1alpha in disease pathogenesis. Am J Respir Crit Care Med (2007) 1.67
Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2009) 1.51
Prevention of nosocomial maxillary sinusitis in the ICU: the effects of topically applied alpha-adrenergic agonists and corticosteroids. Intensive Care Med (2006) 1.48
The efficacy of antithrombin administration in the acute phase of burn injury. Thromb Haemost (2008) 1.46
Interferons and their application in the diseases of the lung. Chest (2003) 1.45
Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest (2005) 1.39
The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer (2009) 1.29
A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med (2013) 1.21
Long-term effect of continuous positive airway pressure therapy on inflammation markers of patients with obstructive sleep apnea syndrome. Sleep (2009) 1.21
Video-assisted thoracoscopic surgery for thoracic empyema: primarily, or after fibrinolytic therapy failure? Am J Surg (2004) 1.17
Fat embolism syndrome: clinical examination is still the preferable diagnostic method. Chest (2003) 1.15
Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Chest (2007) 1.14
Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol (2012) 1.13
Transport of airborne pollen into the city of Thessaloniki: the effects of wind direction, speed and persistence. Int J Biometeorol (2004) 1.11
The effect of obesity on pulmonary lung function of school aged children in Greece. Pediatr Pulmonol (2009) 1.10
Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin? Am J Respir Crit Care Med (2013) 1.09
The predictive role of serum and bronchoalveolar lavage cytokines and adhesion molecules for acute respiratory distress syndrome development and outcome. Respir Res (2002) 1.08
Obstructive sleep apnea aggravates glycemic control across the continuum of glucose homeostasis. Am J Respir Crit Care Med (2010) 1.08
COPD and IPF: it's all about regulation and balance. Thorax (2014) 1.07
Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. J Transl Med (2011) 1.07
Evaluation of health-related quality-of-life and dyspnea scales in patients with idiopathic pulmonary fibrosis. Correlation with pulmonary function tests. Eur J Intern Med (2005) 1.06
Acute fibrinous and organising pneumonia: a case report and review of the literature. J Med Case Rep (2009) 1.05
A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. J Infect (2009) 1.05
Fifteen years' record of airborne allergenic pollen and meteorological parameters in Thessaloniki, Greece. Int J Biometeorol (2003) 1.04
The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J (2012) 1.03
Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest (2006) 1.02
Smoking acutely increases plasma ghrelin concentrations. Clin Chem (2006) 1.01
Early coagulation disorders after severe burn injury: impact on mortality. Intensive Care Med (2008) 1.00
γ-H2AX expression detected by immunohistochemistry correlates with prognosis in early operable non-small cell lung cancer. Onco Targets Ther (2012) 1.00
Inflammatory markers in middle-aged obese subjects: does obstructive sleep apnea syndrome play a role? Mediators Inflamm (2010) 0.98
Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander? Respir Res (2006) 0.96
Prognostic value of serum tumor markers in patients with lung cancer. Respiration (2002) 0.96
Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema. BMC Pulm Med (2013) 0.96
Community acquired bacterial pneumonia. Expert Opin Pharmacother (2010) 0.95
Pleural effusions in critically ill patients. Respiration (2008) 0.95
Induced sputum CD8+ T-lymphocyte subpopulations in chronic obstructive pulmonary disease. Respir Med (2004) 0.95
Intrapleural streptokinase for pleural infection. BMJ (2006) 0.94
The relationships among hydrogen peroxide in expired breath condensate, airway inflammation, and asthma severity. Chest (2002) 0.94
Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. Lung Cancer (2004) 0.94
HbA1c is associated with severity of obstructive sleep apnea hypopnea syndrome in nondiabetic men. Vasc Health Risk Manag (2009) 0.93
Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. J Interferon Cytokine Res (2006) 0.92
Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther (2006) 0.92
Lung cancer and interstitial lung diseases: a systematic review. Pulm Med (2012) 0.92
Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med (2012) 0.92
Combined pulmonary fibrosis and emphysema. Expert Rev Respir Med (2013) 0.91
Exhaled H(2)O(2) in steady-state bronchiectasis: relationship with cellular composition in induced sputum, spirometry, and extent and severity of disease. Chest (2002) 0.91
Stem cell therapy in pulmonary fibrosis. Curr Opin Pulm Med (2011) 0.91
Total antioxidant status in patients with obstructive sleep apnea without comorbidities: the role of the severity of the disease. Sleep Breath (2011) 0.91
Markers of glycemic control and insulin resistance in non-diabetic patients with Obstructive Sleep Apnea Hypopnea Syndrome: does adherence to CPAP treatment improve glycemic control? Sleep Med (2009) 0.91
Comorbidities and chronic obstructive pulmonary disease: is there a place for lung fibrosis? Am J Respir Crit Care Med (2013) 0.90
Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Respiration (2011) 0.90
The cost of COPD exacerbations: a university hospital--based study in Greece. Respir Med (2011) 0.89
Formoterol in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2008) 0.89
Biomarkers in the Evaluation and Management of Idiopathic Pulmonary Fibrosis. Curr Top Med Chem (2016) 0.89
Sleepiness as a marker of glucose deregulation in obstructive sleep apnea. Sleep Breath (2011) 0.89
Recombinant tissue plasminogen activator in the treatment of pleural infections in adults. Respir Med (2008) 0.88
Clinical features of lung cancer in patients with connective tissue diseases: a 10-year hospital based study. Respir Med (2008) 0.88
Continuous positive airway pressure treatment in patients with sleep apnoea: does it really improve glucose metabolism? Curr Diabetes Rev (2010) 0.88
Lower respiratory tract infections caused by Haemophilus influenzae: clinical features and predictors of outcome. Med Sci Monit (2009) 0.87
Sleep apnea syndrome and diastolic blood pressure elevation during exercise. Respiration (2004) 0.87
Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma. Cancer (2008) 0.87
Expression of hypoxia-inducible factor (HIF)-1a-vascular endothelial growth factor (VEGF)-inhibitory growth factor (ING)-4- axis in sarcoidosis patients. BMC Res Notes (2012) 0.87
Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J (2002) 0.87
Stem cell treatment for chronic lung diseases. Respiration (2013) 0.87
Stem cell therapy in chronic obstructive pulmonary disease. Seeking the Prometheus effect. Curr Drug Targets (2013) 0.86
Sleep-disordered breathing and quality of life of railway drivers in Greece. Chest (2008) 0.86
Anemia of chronic disease in chronic obstructive pulmonary disease: a case-control study of cardiopulmonary exercise responses. Respiration (2011) 0.86
Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis. Respir Med (2007) 0.86
Prevalence and clinical characteristics of obesity hypoventilation syndrome among individuals reporting sleep-related breathing symptoms in northern Greece. Sleep Breath (2010) 0.86
Current evidence for the management of paediatric parapneumonic effusions. Curr Med Res Opin (2012) 0.86
Combined pulmonary fibrosis and emphysema associated with microscopic polyangiitis. Eur Respir J (2012) 0.85
Serum biomarkers in interstitial lung diseases. Respir Res (2005) 0.85
Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis. Biomed Res Int (2013) 0.85
Conservative management for an esophageal perforation in a patient presented with delayed diagnosis: a case report review of the literature. Cases J (2009) 0.85
Serum biomarkers in acute respiratory distress syndrome an ailing prognosticator. Respir Res (2005) 0.85
Down-regulation of the inhibitor of growth family member 4 (ING4) in different forms of pulmonary fibrosis. Respir Res (2009) 0.85
Th1/Th2 cytokine pattern in bronchoalveolar lavage fluid and induced sputum in pulmonary sarcoidosis. BMC Pulm Med (2005) 0.84
Diagnostic value of interleukin-1alpha, interleukin-6, and tumor necrosis factor in pleural effusions. Chest (2002) 0.84
Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway. Cancer Lett (2008) 0.84
Efficacy and safety of erythromycin as sclerosing agent in patients with recurrent malignant pleural effusion. Am J Clin Oncol (2008) 0.84
Current pharmacological treatment of pulmonary arterial hypertension. Curr Clin Pharmacol (2008) 0.83
A trial of intrapleural streptokinase. N Engl J Med (2005) 0.83
Autophagy and Bcl-2/BNIP3 death regulatory pathway in non-small cell lung carcinomas. APMIS (2012) 0.82
Decreased apoptotic rate of alveolar macrophages of patients with idiopathic pulmonary fibrosis. Pulm Med (2012) 0.82
Predictors of obstructive sleep apnea in males with metabolic syndrome. Vasc Health Risk Manag (2010) 0.82
Quality of life in patients with active sarcoidosis in Greece. Eur J Intern Med (2006) 0.82
Autoimmunity and chronic obstructive pulmonary disease: thinking beyond cigarette smoke. Am J Respir Crit Care Med (2012) 0.82
8-Isoprostane, a marker of oxidative stress, is increased in the expired breath condensate of patients with pulmonary sarcoidosis. Chest (2004) 0.82
Determinants of continuous positive airway pressure compliance in a group of Greek patients with obstructive sleep apnea. Eur J Intern Med (2009) 0.82
Assessment of respiratory mechanics by impulse oscillometry in orthopneic patients with acute left ventricular failure. Heart Lung (2010) 0.82
Epstein-Barr virus DNA in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis (2007) 0.81
E-cadherin expression on fine-needle aspiration biopsies in primary lung adenocarcinomas is related to tumor differentiation and invasion. Anticancer Res (2003) 0.81
Steep barriers to overcome for successful application of stem cell treatment in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2013) 0.81